LIZY WINDSOR: Open Payments
NPI 1912514878 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,544 in 131 payments from 17 companies in 2025. Trend: 2023 $1,339 · 2024 $1,979 · 2025 $2,544
Food & beverage: $2,544
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $608 |
| E.R. Squibb & Sons, L.L.C. | 15 | $268 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $237 |
| Otsuka America Pharmaceutical, Inc. | 14 | $223 |
| Alkermes, Inc. | 9 | $185 |
| Teva Pharmaceuticals USA, Inc. | 10 | $173 |
| Vanda Pharmaceuticals Inc. | 5 | $158 |
| Indivior Inc. | 5 | $155 |
| Almatica Pharma LLC | 6 | $113 |
| Lundbeck LLC | 5 | $91 |
Products named: VRAYLAR, COBENFY, REXULTI, CAPLYTA, FANAPT, SUBLOCADE, AUSTEDO XR, ARISTADA.
Industry payments across AZ — which companies pay providers there.
